PP59. NON SPECIFIC CHROMOSOME DELETION IN M3 NON-LYMPHOCYTIC LEUKEMIA
G. ILIEVA1, L. Cevreska2 and M. Kocova1 1. Pediatric Clinic, Medical Faculty, Skopje, Republic of Macedonia 2. Clinic for Hematological diseases, Medical Faculty, Skopje, Republic of Macedonia e-mail: anet@freemail.com.mk
*Corresponding Author:
page: 74

Abstract

Cytogenetic analysis is important for the diagnosis, therapeutic approach and follow-up of malignant diseases. Specific chromosomal changes in leukemia are important prognostic tool. Translocation t (15;17) (q22;q11-12) is highly specific for M3 (promyelocytic) leukemia and has not been detected in any other malignancy so far. Case report: A man at age 59 years had clinical manifestations of M3 leukemia. Bone marrow showed significant hypercellularity accompanied by megaloblastic erythroid lineage, high number of dysplastic megakaryocytes, PAS negativity, POX negativity, AF negativity, and positive esterase. All findings were concordant with the diagnosis of promyelocytic leukemia AML-M3. Cytogenetic analysis performed by the standard direct technique from the bone marrow showed significant polyploidy and deletion 17 (q11-12) in all analyzed metaphases. This was unfavorable sign for M3 leukemia. The patient did not respond to AIDA protocol and expired shortly after the initiation of the therapy. It has been documented that during the translocation t (15;17) fusion of PM/RARA genes occurs increasing sensitivity of AML-M3 cells towards standardized ATRA (all-trans-retionic-acid) protocol. Sensitivity to ATRA is crucial since it leads to resolution of disseminated intravascular coagulation and promotes remission. Only patients with t (15; 17) respond favorably to ATRA protocol. In our patient, although the break point on the chromosome 17 was the same as in the specific translocation, fusion PM/RARA failed to occur, thus his response to treatment was poor. In conclusion, cytogenetic analysis in M3 leukemia is beneficial since it might help choice of the therapeutic protocol.




Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006